Revenue (Quarterly) Chart

View Revenue (Quarterly) for MYGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 190.70M
March 31, 2026 200.40M
December 31, 2025 209.80M
September 30, 2025 205.70M
June 30, 2025 213.10M
March 31, 2025 195.90M
December 31, 2024 210.60M
September 30, 2024 213.30M
June 30, 2024 211.50M
March 31, 2024 202.20M
December 31, 2023 196.60M
September 30, 2023 191.90M
June 30, 2023 183.50M
March 31, 2023 181.20M
December 31, 2022 177.80M
September 30, 2022 156.40M
June 30, 2022 179.30M
March 31, 2022 164.90M
December 31, 2021 160.80M
September 30, 2021 167.30M
June 30, 2021 189.40M
March 31, 2021 173.10M
June 30, 2020 93.20M
March 31, 2020 164.00M
December 31, 2019 195.10M
Date Value
September 30, 2019 186.30M
June 30, 2019 215.40M
March 31, 2019 216.60M
December 31, 2018 216.80M
September 30, 2018 202.30M
June 30, 2018 193.90M
March 31, 2018 183.10M
December 31, 2017 187.90M
September 30, 2017 178.80M
June 30, 2017 200.50M
March 31, 2017 196.90M
December 31, 2016 196.50M
September 30, 2016 177.50M
June 30, 2016 186.50M
March 31, 2016 190.50M
December 31, 2015 193.30M
September 30, 2015 183.50M
June 30, 2015 189.90M
March 31, 2015 179.98M
December 31, 2014 184.39M
September 30, 2014 168.84M
June 30, 2014 188.77M
March 31, 2014 182.92M
December 31, 2013 204.06M
September 30, 2013 202.47M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Natera, Inc. 752.75M
Sera Prognostics, Inc. 0.03M
BioRestorative Therapies, Inc. 0.0232M
CareDx, Inc. 131.95M
Exagen, Inc. 19.94M